Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Thursday, September 29, 2011

Agenix submits manufacturing patent application for hepatitis B drug AGX-1009

Agenix said it had filed an international method of manufacture patent application under the Patent Cooperation Treaty (PCT) for its hepatitis B drug AGX-1009. The application covers the manufacturing process of a compound that uses the same active ingredient, Tenofovir, used in the US Food and Drug Administration (US FDA) approved drug marketed by Gilead Sciences under the trade name Viread.

The international application aims to provide further long-term protection for the company’s platform hepatitis B drug compounds through until 2030. Agenix already has a registered patent to protect the AGX-1009 compound in China through to 2026. Like Viread, AGX-1009 is a so-called ‘prodrug' of Tenofovir. Gilead’s ‘prodrug’ of Tenofovir was approved for treatment of hepatitis B in the US in 2008 and in numerous countries globally but is not yet approved in China. Both drugs contain Tenofovir but have different molecular side chains to activate that compound. Both drugs work by blocking an enzyme the hepatitis virus needs to replicate.

Read more....

No comments:

Post a Comment